首页> 外文期刊>Pharmaceutical statistics. >Optimal adaptive sequential designs for crossover bioequivalence studies
【24h】

Optimal adaptive sequential designs for crossover bioequivalence studies

机译:交叉生物等效性研究的最佳自适应顺序设计

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In prior works, this group demonstrated the feasibility of valid adaptive sequential designs for crossover bioequivalence studies. In this paper, we extend the prior work to optimize adaptive sequential designs over a range of geometric mean test/reference ratios (GMRs) of 70-143% within each of two ranges of intra-subject coefficient of variation (10-30% and 30-55%). These designs also introduce a futility decision for stopping the study after the first stage if there is sufficiently low likelihood of meeting bioequivalence criteria if the second stage were completed, as well as an upper limit on total study size. The optimized designs exhibited substantially improved performance characteristics over our previous adaptive sequential designs. Even though the optimized designs avoided undue inflation of type I error and maintained power at 80%, their average sample sizes were similar to or less than those of conventional single stage designs. Copyright (c) 2015 John Wiley & Sons, Ltd.
机译:在先前的工作中,该小组证明了有效的自适应顺序设计用于交叉生物等效性研究的可行性。在本文中,我们扩展了先前的工作,以在受试者内部变异系数的两个范围(分别为10-30%和70%)之间的70-143%的几何平均测试/参考比(GMR)范围内优化自适应顺序设计。 30-55%)。如果第二阶段完成后,如果满足生物等效性标准的可能性很低,则这些设计还提出了一个无效的决定,即在第一阶段后停止研究,以及上限为总研究规模。与我们以前的自适应顺序设计相比,优化的设计展现出显着改善的性能特征。即使优化的设计避免了I型误差的过度膨胀,并且将功率保持在80%,但它们的平均样本大小与传统单级设计的大小相似或更少。版权所有(c)2015 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号